InsiderClue
← All stocks

Contineum Therapeutics, Inc.

CTNM Scheduled selling only
CIK 0001855175 #2951 in the set updated 17 Sep 2026
Bought (1 mo)
$0.00
out of their own pocket, the only kind of buying there is
Sold (1 mo)
$41.14K
$0.00 on a plan · $41.14K straight out of an exercise
Sold at will
$0.00
0 of 1 sales
Net
−$41.14K
$0.00 against sales at will

By person

3 insiders · 1 transaction
0.4×

Carmine N. Stengone holds only 0.4 times base salary in stock. $283.33K of shares against $655.62K in salary for 2025.

Salary from the company's own proxy. The shares are what Carmine N. Stengone last reported holding, valued at $16.46, the price Class A Common Stock was last bought or sold at on the open market here, on 8 Sep 2026.

Insider
Role
Bought
Sold
Net
Holding
Of company
Worth
Change
Stengone Carmine N.
CEO and President
—
$41.14K (1) scheduled
−$41.14K
17,217
0.0745%
$283.33K
0.0%
Lorrain Daniel S.
Chief Scientific Officer
—
—
—
135,202
0.5853%
$2.22M
−23.1%
Watkins Tim
CMO & Head of Development
—
—
—
8,961
0.0388%
$147.47K
0.0%

Individual transactions

1
Insider
Date
Role
Action
Shares
Price
Amount
Stengone Carmine N.
8 Sep 2026
CEO and President
Sold after exercise
2,500
$16.46
$41.14K
Show all 1 transactions →

What was left out

Form 4 filings counted 1
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 0
Sales straight out of an exercise 1
Sales at will 0
Transactions with no price 0
Shares from compensation/vesting 2,500
History held since 11 Apr 2024